Nxera Pharma's partner Neurocrine Biosciences has dosed the first patient in a Phase 2 trial of NBI-1117570, an oral drug targeting muscarinic M1/M4 receptors for adults with schizophrenia. This milestone triggers $22.5 million in payments to Nxera, recognized in Q1 FY2026. The trial will enroll about 120 patients to evaluate the drug's efficacy and safety, aiming to address significant unmet needs in schizophrenia treatment. Nxera's proprietary NxWave™ platform discovered the drug, highlighting ongoing collaboration progress.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
QuickLogic and PQSecure Technologies demonstrated that PQSecure's CRYSTAL-1000C post-quantum cryptographic IP can be efficiently implemented on QuickLogic's reprogrammable eFPGA fabric within SoCs. This allows field-upgradeable security without costl...
Relmada Therapeutics, a clinical-stage biotech company focused on oncology and CNS therapies, will announce its financial results for Q2 2026 on August 6, 2026. The company will host a conference call and webcast to discuss the results and recent bus...
Gilat Satellite Networks Ltd., a global leader in satellite networking technology, will release its second quarter 2026 financial results on August 5, 2026. Following the release, CEO Adi Sfadia and CFO Gil Benyamini will hold a conference call and w...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
